

1

2 **Antimicrobial Treatment Imprecision: An Outcome-Based**
3 **Model to Close the Data-To-Action Loop**

4

5

6 Alex Howard^{1,2*} MBChB, Nada Reza¹ MBChB, Stephen Aston¹ PhD, Beth Woods³ MSc,
7 Alessandro Gerada^{1,2} MD, Prof. Iain Buchan⁴ PhD, Prof. William Hope^{1,2} PhD, Anne-Grete
8 Mårtson¹ PhD

9

10 ¹Department of Antimicrobial Pharmacodynamics and Therapeutics, Institute of Systems,
11 Molecular and Integrative Biology, William Henry Duncan Building, 6 West Derby Street,
12 University of Liverpool, Liverpool L7 8TX, UK

13 ²Department of Infection and Immunity, Liverpool Clinical Laboratories, Clinical Support
14 services Building, Liverpool University Hospitals NHS Foundation Trust – Royal Liverpool
15 Site, Mount Vernon Street, Liverpool L7 8YE, UK

16 ³Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK

17 ⁴Department of Public Health, Policy & Systems, Institute of Population Health, University of
18 Liverpool, Waterhouse Building Block B, Brownlow Street, Liverpool, L69 3GF, UK

19 *Corresponding author

20 Alex Howard

21 email: alexander.howard@liverpool.ac.uk

22

23

24 **Summary**

25

26 Healthcare systems, food supply chains, and society in general are threatened by the
27 inexorable rise of antimicrobial resistance. This threat is driven by many factors, one of
28 which is inappropriate antimicrobial treatment. The ability of policymakers and leaders in
29 healthcare, public health, regulatory agencies, and research and development to deliver
30 frameworks for appropriate, sustainable antimicrobial treatment is hampered by a lack of
31 tangible outcome-based measures of the damage it causes. In this review, a mathematically
32 grounded, outcome-based measure of antimicrobial treatment appropriateness,
33 'imprecision', is proposed. We outline a framework for policymakers and healthcare leaders
34 to use this metric to deliver more effective antimicrobial stewardship interventions into future
35 patient pathways. This will be achieved using 'learning antimicrobial systems' built on public
36 and practitioner engagement, solid implementation science, advances in artificial
37 intelligence, and changes to regulation, research, and development. The outcomes of this
38 framework would be more ecologically and organisationally sustainable patterns of
39 antimicrobial development, regulation, and prescribing. We discuss practical, ethical, and
40 regulatory considerations involved in delivery of novel antimicrobial drug development, policy
41 and patient pathways built on artificial intelligence-augmented measures of antimicrobial
42 treatment imprecision.

43

44

1. Introduction

Antimicrobial agents underpin healthcare systems, sustainable food production, and safe, prosperous societies world-wide.^{1,2} These benefits, however, are threatened by rising antimicrobial resistance (AMR). Inappropriate antimicrobial treatment in healthcare is an important driver of AMR, helping to perpetuate ecologically unsustainable cycles of ‘boom-and-bust’ between AMR emergence and antimicrobial discovery and development (Figure 1).^{3,4}




Figure 1: ‘Boom-and-bust’ cycles of antimicrobial discovery, development, prescribing and AMR as a contributor and response to the emergence of increasingly antimicrobial-resistant organisms. CRE: Carbapenem resistant Enterobacteriales, VRE: Vancomycin resistant *Enterococcus*, CRAB: Carbapenem resistant *Acinetobacter baumannii*, CRPA: Carbapenem resistant *Pseudomonas aeruginosa*, MRHP: Macrolide resistant *Helicobacter pylori*, VRSA/VISA: Vancomycin resistant/intermediate *Staphylococcus aureus*, MRSA: Methicillin resistant *Staphylococcus aureus*, ESBL: Extended-spectrum beta-lactamase, MSSA: Methicillin-resistant *Staphylococcus aureus*^{5,6}

Antimicrobial stewardship (AMS) aims to improve the appropriateness of antimicrobial treatment using frameworks such as The World Health Organisation’s (WHO) Access, Watch, Reserve (AWaRe) classification.^{7,8} These frameworks, however, do not necessarily quantify the imprecision of antimicrobial treatment in terms of its full individual and population costs in healthcare. These costs may include:

- Suboptimal outcomes caused by treatment failure and/or unanticipated toxicity (e.g., *Clostridioides difficile* diarrhoea, drug toxicity).⁹
- Emergence of multidrug resistant (MDR)/extensively drug resistant (XDR) organisms leading to treatment failure and creating the potential for their horizontal spread.^{10,11}
- Financial costs incurred by poorly targeted use of expensive new drugs.¹²

Failure to routinely consider and capture the full cost of antimicrobial therapy hinders the design of policy in multiple sectors including healthcare, public health, regulation, and research and development (R&D). Integrated data from digitisation of healthcare records, new

78 diagnostics, and One Health AMR studies (e.g., in agricultural antimicrobial use, water
79 cleanliness) could help better quantify the true impact of antimicrobial therapy. However, this
80 opportunity is lost because of fragmented dataflows within and between global healthcare
81 settings.¹³

82 Here, we propose an outcome-based model for policymakers and healthcare leaders
83 worldwide to deliver better antimicrobial treatment outcomes for their citizens. This model is
84 built on quantification of ‘imprecision’, which we define as the difference between the total
85 effect of antimicrobial treatment and the effect that is required to provide the best overall
86 (individual and societal) outcome. We outline an approach for reducing imprecision in patient
87 pathways via:

- 88 1. Developing a quantitative model of imprecision based on individual and population-
89 based outcome measures, biologically plausible covariates, and artificial intelligence
90 (AI) techniques.
- 91 2. Identifying and understanding systemic and behavioural drivers of imprecision in
92 healthcare that can be used to parameterise and calibrate models of imprecision and
93 design a range of interventions to improve precision.
- 94 3. Outlining the improvements in data inputs, interpretation, and actionability required for
95 collaborations of policymakers and healthcare leaders to build ‘learning antimicrobial
96 systems’ (LASs) that will deliver the individual and societal benefits of more precise
97 antimicrobial therapy. We consider the role of healthcare providers, R&D,
98 patient/practitioner/public engagement, data stewardship, implementation science, and
99 regulatory bodies in the delivery of these systems.

100
101

102 **1.1 Search strategy and selection criteria**

103

104 For major topics/concepts, advanced searches of Google Scholar for articles from the last 25
105 years utilised combinations of the terms “antimicrobial”, “resistance”, “prescribing”,
106 “stewardship”, “artificial intelligence”, “machine learning”, “bayesian”, “epidemiology”, “drug
107 development”, “decision”, “outcome”, “data”, “diagnostics”, “public health”, “health
108 economics”, “policy”, and “regulation”. Searches for minor topics/concepts (e.g., “pill-in-
109 pocket”) and known documents (e.g., WHO AWaRe) utilised relevant targeted search terms.
110 Manual result searches determined sources for inclusion based on relevance.

111

112

113 **2. Imprecision: a measure of antimicrobial treatment inappropriateness**

114 Measures of the appropriateness of antimicrobial therapy monitored by AMS programmes
115 and public health agencies are often based on the volume of antimicrobial use and
116 adherence to population-level guidelines. The consequences of antimicrobial use are often
117 inferred from aggregate-level trends (e.g., local AMR rates).

118 Optimally precise antimicrobial use requires a conceptual framework that uses an outcome-
119 based model to capture and quantify the total impact of antimicrobial treatment. Table 1
120 summarises important concepts that will be introduced and used here in developing this
121 model.

122

Term	Definition
Antimicrobial treatment imprecision	The difference between the total effect of antimicrobial treatment and the effect which is required to provide the greatest benefit, i.e., the best outcome once individual and societal needs are considered.

Artificial intelligence (AI)	The ability of algorithms to perform cognitive functions typical of human brains (e.g., perception, reasoning, learning, interacting with the environment, problem solving, and decision making).
Decision node	A time point in an individual's healthcare journey (pathway) where a decision is made that affects their ongoing antimicrobial treatment. There are three decision nodes, which correspond to starting, changing, and stopping treatment.
Deficit imprecision	An antimicrobial is not exerting enough intended effect to provide the greatest overall benefit in terms of 'total effect of antimicrobial treatment' (see below).
Excess imprecision	An antimicrobial is exerting non-intended effects which reduce overall benefit in terms of 'total effect of antimicrobial treatment' (see below).
Explainable artificial intelligence	Model frameworks that enable machine learning algorithm predictions to be understood and interpreted.
Learning antimicrobial system (LAS)	A set of processes built on integration of real-time dataflows and prediction techniques that enables continuous learning from, and reduction of, antimicrobial treatment imprecision.
Machine learning (ML)	A subdiscipline of artificial intelligence in which computer systems develop statistical models and predictions by making inferences from data.
Neural network	A set of artificial intelligence algorithms that aim to interpret data in a way that mimics the processes of a human brain.
Supervised learning	A subdiscipline of machine learning where algorithms map predictions between data labelled as inputs (covariates) and outputs (outcomes).
Total effect of antimicrobial treatment	An overall measure of all individual and population effects of antimicrobial treatment.
Unsupervised learning	A subdiscipline of machine learning where algorithms infer clusters and/or patterns in data not labelled as inputs (covariates) or outputs (outcomes).

Table 1: A glossary of important concepts introduced and used here in developing and considering implementation of a model of antimicrobial treatment imprecision¹⁴⁻¹⁷

2.1 Outcome measure: defining, detecting and quantifying imprecision

The potential effects of imprecision (I_t) can be considered in terms of deficit and excess (See Figure 2), which align with 'benefit and risk' in antimicrobial prescribing decisions:

- Deficit (I_d): antimicrobial treatment is exerting insufficient effect to provide the greatest overall individual and population benefit (e.g., inadequate treatment response).
- Excess (I_e): antimicrobial treatment is exerting non-intended effects that reduce overall individual and population benefit (e.g., nephrotoxicity, *C. difficile* diarrhoea, AMR emergence, subsequent person-to-person transmission of AMR).¹⁸




Figure 2: A conceptual model of antimicrobial therapy imprecision as a directional measure of difference in alignment between the effect of an antimicrobial and the effect needed to achieve the 'greatest benefit', i.e., the best overall outcome when both individual and societal needs are considered. I_d = deficit imprecision, I_e = excess imprecision.

Quantifying imprecision with this directional model presents four problems:

1. Analysing scenarios with coexisting deficit and excess imprecision demonstrates that they can be difficult to demarcate. For example, both uncontrolled sepsis and aminoglycoside therapy can cause nephrotoxicity.
2. Some forms of excess and deficit are difficult to detect (e.g., AMR emergence in an individual patient), particularly in terms of the impact on populations and 'distant others'.
3. Clinical scenarios are too complex to precisely determine the minimum effect required to avoid deficit imprecision and vice versa.
4. Plausible biological outcomes of excess and deficit do not necessarily result in impact that is meaningful for patients. For example, the impact of nephrotoxicity could range from a transient rise in serum creatinine to a lifetime of haemodialysis.

Measures of deficit and excess could therefore be used to screen for scenarios where antimicrobial imprecision may be present. For example, carbapenem treatment of bacteraemia caused by a carbapenem-resistant organism could plausibly be linked to prior carbapenem use (potential excess) and death from the bacteraemia (potential deficit). Employment of new scientific techniques (e.g., 'microbiomics', molecular epidemiology, ambient sensor tracking of movement in healthcare environments) will be key to detecting hidden imprecision events such as selection pressure, mutational events, and transmission.⁴⁸

Imprecision modelling cannot not make subjective assessments about 'quality' of prescribing decisions. It could instead use Bayesian modelling of clinical covariates (as discussed in Section 2.2) to objectively estimate the most plausible probabilities of different outcomes following different prescribing decisions. These outcomes should be meaningful for patients in terms of how they 'feel, function, and survive' (e.g., patient-reported outcome measures and all-cause mortality). Aggregate population health perspective (APHP) health economic

169 analyses could then model the effects on society and ‘distant others’ (i.e., people whom the
 170 patient does not come into direct contact with) using combined health outcome measures
 171 (e.g., quality-adjusted life years [QALYs], disability adjusted life years [DALYs]).

172

173 **2.2 Covariates: predictors of imprecision in patient pathways**

174

175 Imprecision outcomes are influenced by a diverse range of (unmeasured and/or causally
 176 unlinked) covariates individual to patient, infection, organism, microbiome, and population.
 177 Mixed effects Bayesian logistic regression models could contain and weight such effects as
 178 random coefficients (γ) with multiple mechanistically plausible measures of potential deficit
 179 and/or excess imprecision ($I_t = \alpha + \alpha_r + \beta_1\beta_1I_1 + \beta_1\beta_2I_2 + \dots$). Examples of mechanistically
 180 plausible factors influencing clinical response (potential deficit) and AMR generation
 181 (potential excess) that may be appropriate for inclusion in such models are summarised in
 182 Table 2.

183

Clinical Response (potential deficit)	AMR Generation (potential excess)	Clinical Response & AMR Generation (potential excess and deficit)
Time to initiation of therapy	Mechanistic liability of antimicrobial agent to generate mutational resistance (e.g., drugs affecting multiple microbiological targets may be less liable to generate resistance)	Length of antimicrobial treatment course
Age	Liability of infecting organism species to develop new mutational resistance (e.g., penicillins for β haemolytic streptococci vs <i>Pseudomonas</i> species)	Microbial burden of disease in terms of the likely number of infecting organisms (e.g., abscess vs urinary tract infection)
Illness severity (e.g., APACHE II)	..	Adjunctive treatments (e.g., surgical source control)
Pharmacogenetic determinants of toxicity	..	Penetration of antimicrobial agent into site of infection in adequate concentrations to achieve logarithmic killing (e.g., intra-abdominal abscess, central nervous system, or intra-ocular infection)
Allergy history affecting use of first-line agents	..	Comorbidities including persistently impaired host immunity (e.g., profound prolonged neutropenia)
Drug-drug interactions	..	Microbial spectrum of coverage of antimicrobial agent
Pharmacokinetic properties of agent (e.g., action based on peak concentration vs time over minimum inhibitory concentration)	..	Number of antimicrobial agents used with activity against the infecting organism
Virulence factors of infecting organism species (e.g., β haemolytic streptococci vs coagulase-negative staphylococci)

184

185 Table 2: Examples of mechanistically plausible factors that could be associated with clinical response (potential
 186 deficit), AMR generation (potential excess), or both clinical response and AMR generation (potential excess and
 187 deficit), that could be used to parameterise Bayesian predictive models of imprecision in antimicrobial treatment.

188

189

190 Interdisciplinary statistical and microbiological expertise and counterfactual (sensitivity)
191 analysis gives the best chance of selecting mechanistically plausible covariates. However,
192 their predictive value may still be overwhelmed by statistical ‘noise’ from factors that are
193 measurable and predictive but not causally intuitive.

194 Advances in computing power and statistical methods have led to statistical machine
195 learning (ML) that is causally principled and capable of being grounded by clinical
196 counterfactual scenarios. There is uncertainty as to whether ML models should extend to
197 ‘unsupervised’ modelling techniques that do not incorporate biological causative
198 mechanisms. Such causation-agnostic, unsupervised learning could surface complex
199 associations in causally unlabelled patient pathway data. These algorithms may recognise
200 and predict causally counter-intuitive ‘fingerprints’ of imprecision by forming complex and
201 opaque deep learning neural networks to navigate sequences (and timing) of events in
202 patient pathways. Such ‘black box’ approaches have challenges to overcome including lack
203 of principled transferability between healthcare settings, and lack of
204 patient/public/practitioner trust in non-explainable models. Unsupervised ML algorithms
205 could theoretically screen for imprecision, but the ‘label-free explainability’ techniques
206 required to create a meaningful, actionable unified model do not (yet) exist. Currently, mixed
207 algorithmic approaches combining supervised and unsupervised ML are likely to be the most
208 implementable.

209
210
211

3. Key drivers of imprecision in healthcare pathways

212 Imprecision is driven by complex, interacting psychological, sociological, biological, and
213 system factors. Healthcare data which policymakers and healthcare leaders could use to
214 detect and manage these factors is currently insufficient, unlinked, unvalued, and
215 insufficiently actionable (Figure 3).




Figure 3: The current imprecise approach to healthcare data flows in patient pathways. Antimicrobial decision nodes in existing antimicrobial treatment pathways fed by clinical, diagnostic, R&D, and policy data. Imprecision is exacerbated by fragmented dataflows from multiple sources that are used to inform attending clinicians, population-level guidelines, policymakers, regulatory bodies, and R&D stakeholders. These dataflows fail to feed personalised, precise information back into the patient pathway, resulting in unnecessary costs to patients and populations.

3.1 Data inputs: insufficient, unlinked, and unvalued

Data inputs in many healthcare pathways globally are:

- Insufficient: electronic healthcare records and diagnostic innovations reduce diagnostic uncertainty by improving data availability, accuracy, and timeliness for decision makers. Leveraging these technologies to reduce treatment imprecision is affected by incomplete uptake and variations in availability globally. Some traditional data inputs are being eroded (e.g., telemedicine depriving clinicians of face-to-face sensory information).²⁸
- Unlinked: fragmentation of healthcare economies often results in poorly integrated dataflows to, from, and between healthcare providers (Figure 3). Decisions are therefore often made based on incomplete information.²⁹

- 237
- 238
- 239
- 240
- 241
- 242
- Undervalued: the information provided by data and analytics is often poorly understood and valued by clinicians, patients, and policymakers. New diagnostic tests are deployed in disconnected tendering, procuring, contracting and implementation processes. Their potential impact is therefore not realised, and their potential value not recognised. Undervalued, untargeted data collection also risks harming public trust in how their data are used.³⁰

243

244 **3.2 Data actionability: decision making in healthcare**

245

246 To understand prescriber drivers (and therefore intervention targets) of antimicrobial
247 treatment imprecision in patient pathways, it is informative to consider the component parts
248 of three prescribing decision nodes: starting, changing, and stopping antimicrobial treatment.

249

250 **3.2.1 Decision node 1: starting antimicrobial treatment**

251

252 Starting antimicrobial treatment comprises four decisions:

- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
- 261
- 262
- 263
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273
- 274
- 275
- 276
- 277
- 278
- 279
- 280
- 281
- 282
- 283
- 284
- 285
- 286
- 287
- 288
- 289
1. Whether to commence treatment: where infections are part of differential diagnoses, empirical treatments bridge early uncertainty in patient pathways. Crucial new technologies, diagnostics, biomarkers, and therapeutic drug monitoring (TDM) cannot resolve this uncertainty alone because their impact in the context of human and healthcare system factors is incompletely understood – healthcare workers are under unprecedented time pressure and increasing administrative burden.³¹ Perceived small margins of error and prior experience (e.g., previous death of a patient following insufficient antimicrobial treatment) can skew perceptions of risks, benefits and loss.³² Antimicrobial treatment is therefore often perceived as the ‘safe’ option.^{33,34} Biases towards heuristic, imprecise prescribing decisions result, which can become embedded in organisational practices and become culturally engrained.³⁵ Patients are rarely counselled as to the consequences of imprecision, exacerbating behavioural patterns of antimicrobial-seeking particularly in primary care.
 2. Agent choice: the range of available agents is determined by drug development processes and frameworks that incentivise imprecision – broader organism spectrum coverage broadens the range of potential licensed clinical indications. Empirical treatment of infection syndromes (e.g., urinary tract infection) is predominantly directed by guidelines/formularies based on population-level data. Working diagnoses in periods of diagnostic uncertainty (e.g., ‘sepsis of unknown origin’ at initial presentation to healthcare) are often treated with broad-spectrum antimicrobial treatment. Colonisation status, comorbidities and risk of specific pathogens may facilitate more targeted therapy. However, their application is inconsistent in clinical practice, and their predictive value is not always understood.³⁶ Infection severity is often highest at initial presentation, increasing the likelihood of imprecise treatment in the face of perceived narrow margins of error.³⁷ Decision aids based on snapshots of context-specific observational data are often used to direct agent choice (e.g., CURB-65 in pneumonia). These are useful methods for leveraging evidence-based medicine in patient pathways. However, they may generalise inadequately beyond original populations and lack evidence-based implementation approaches.³⁸
 3. Route of administration: patients may receive parenteral antimicrobial therapy for practical reasons (e.g., swallowing difficulties) or to achieve high drug exposure, though highly-bioavailable oral therapy is increasingly used.³⁹
 4. Regimen: recommended dosing regimens are chosen in early clinical trials to maximise chances of efficacy or establish non-inferiority with minimum expenditure – additional time/resource input to identify occult harms of antimicrobial over- and/or under-exposure are not incentivised. Initial dosages can only be individualised using

290 readily observed values (e.g., weight, renal function). Other relevant information
 291 (e.g., pharmacogenetics) are often either not available in clinical practice due to a
 292 poor evidence base and lack of well-designed trials, or too slow to be clinically
 293 useful.^{40,41} There is therefore variability in antimicrobial regimen imprecision ranging
 294 from routine TDM for some agents to 'one-size-fits-all' solutions for others.⁴²
 295 Resource pressures can endanger precise regimens by shifting or distorting the goal
 296 of therapy (e.g., a six-hourly intravenous infusion regimen may be sacrificed for a
 297 more convenient but broad spectrum once-daily regimen to facilitate discharge from
 298 hospital).⁴³

299
 300


3.2.2 Decision node 2: changing antimicrobial treatment

301
 302
 303

Changing treatment also comprises four decisions:

- 304 1. Whether to change treatment: clinicians have high thresholds to challenge legacy
 305 diagnoses made at initial presentation, meaning opportunities to reduce treatment
 306 imprecision are lost. Many clinicians are uncertain how long treatment response
 307 should take, what constitutes adequate response, and what other clinical factors are
 308 relevant.⁴⁴
- 309 2. Changing antimicrobial agent: diagnostic results may reduce treatment imprecision in
 310 several ways – examples of the potential effects of microbiology tests on diagnostic
 311 uncertainty are summarised in Figure 4. Discordance between susceptibility results
 312 and clinical response is common, however, reflecting the importance of clinical
 313 covariates, laboratory measurement and susceptibility breakpoint definitions.^{45,46}

314
 315



316
 317 Figure 4: Examples of effects of microbiology diagnostics on precision of antimicrobial treatment by reducing
 318 diagnostic uncertainty. AST: Antimicrobial susceptibility testing, AMR: Antimicrobial resistance, WBC: White
 319 blood cell.
 320
 321

- 322 3. Changing route of administration: ‘step-down’ to similar spectrum agents with routes
323 of administration facilitating discharge is common.⁴⁷ ‘Escalation’ from oral to
324 intravenous agents in response to severity is often accompanied by broadening of
325 antimicrobial spectrum, though like-for-like escalation can occur to increase drug
326 exposure.^{48,49}
- 327 4. Changing regimen: TDM is a powerful precision tool to maximise effect and minimise
328 toxicity, but its targets may not always reflect biological variability and organism
329 susceptibility is not always quantified.⁵⁰ Pharmacogenetic tests and treatment effect
330 biomarkers are available but uptake in clinical care is poor and interpretation remains
331 problematic (e.g., gentamicin *MT-RNR1* variant and hearing loss).⁵¹ Resistance-
332 suppressing drug exposure targets are have been identified, but their use carries
333 ethical ramifications where individual patient and population benefits/risks are in
334 tension (e.g., where exposure targets for resistance suppression increase likelihood
335 of toxicity).^{52,53}

336

337 **3.2.3 Decision node 3: stopping antimicrobial treatment**

338

339 Guideline-recommended durations of therapy often adhere to multiples of 5-day or 7-day
340 units and are imprecise in many individual situations. Easy-to-remember durations prompt
341 clinicians to think about length of treatment but maintaining the status quo and continuing
342 treatment is often perceived as the ‘safe’ option. For decades, prevailing teaching has been
343 that ‘completing the course’ reduces resistance generation, but this has recently been
344 challenged.⁵⁴ Understanding the imprecision of flexible treatment durations adopted in the
345 best interests of patients with recurrent or resistant infections (e.g., suppressive,
346 prophylactic, or ‘pill-in-pocket’ antimicrobial plans) is difficult due to their relative rarity.^{55–58}

347

348 **4. Implementing precision modelling to close data-to-action loops in healthcare**

349

350 **4.1 Improving data inputs: connected dataflows and new technologies**

351 Accurate, actionable models of imprecision will require ‘big’, real-world, contemporaneous
352 clinical data.⁵⁹ This will necessitate new dataflows into continuously updated repositories
353 with significant storage capacity and data engineering resource. These repositories will
354 combine publicly accessible stores of antimicrobial study data with anonymised individual
355 and aggregate-level electronic health records. They will form platforms for enhanced,
356 continuously tuned systems for real-time data sharing, linkage, curation, and processing.
357 Their encryption and governance processes will permit regulated access to Trusted/Secure
358 Data Environments (TREs/SDEs) for researchers, practitioners, policymakers, and
359 managers. Within healthcare, adoption of commodity AIs for tasks such as natural language
360 processing will improve data structure and availability.⁶⁰

361 Given that AMR is a global problem, expansion of connected dataflows beyond national
362 borders should be the ultimate objective – this will undoubtedly be a significant legislative
363 and technical challenge. Regional/national dataflow networks should be seen as achievable
364 medium-term steppingstones towards that goal. Open-source sharing of algorithms and
365 metadata will help nations to converge on the same goal. For R&D data, international hubs
366 could be built for regulated cross-border access to preclinical data to inform global drug and
367 device development programmes. The way in which encrypted data storage infrastructure
368 can be sustainably funded and built in a range of global income settings (e.g., through cloud
369 data storage and affordable hardware) will be another key consideration.

370 Traditional epidemiological techniques (e.g., population screening) combined with advances
371 in genomic, proteomic, and ambient/wearable biometric technology will fill critical gaps for
372 detecting and quantifying microbiome and transmission outcomes. Integration of healthcare

373 dataflows with One Health agriculture and clean water research will further enhance
374 understanding of the transmission of AMR between people, animals, and the environment.
375 Innovative data inputs with AI-informed R&D pathways will also be required to parameterise
376 predictive models of imprecision (e.g., a wearable or in-line therapeutic drug monitor that
377 models the effect of serum drug levels on treatment imprecision).⁶¹ Advances in molecular
378 diagnostics could improve timeliness of diagnostic information, improving precision and
379 moving antimicrobial decision nodes closer to the start of the patient pathway.⁶² Improved
380 qualitative data collection techniques will help understand and predict human factor drivers
381 of imprecision at decision nodes.

382

383 **4.2 Improving data interpretation: learning antimicrobial systems**

384 Systems built on integrated dataflows have already demonstrated an ability to formulate and
385 effect policy by learning from population-level data.⁶³ Improved data inputs combined with
386 accurate imprecision AI models that link causally-intuitive covariates to aggregative outcome
387 measures of mortality and morbidity (outlined in Section 2) could enable leaders and
388 policymakers to build 'learning antimicrobial systems' (LASs). The running and governance
389 of these systems would incorporate health and social care, public health, regulatory and
390 R&D stakeholders, and continuously adapt to real-time, real-world data, enabling R&D,
391 policy, and patient pathways to be mapped, analysed, simulated, and controlled.⁶⁴


392 Examples of the interpretive applications of an LAS in healthcare provider organisations,
393 policymaking/regulatory agencies, and R&D include:

- 394 ● Understanding the impact of diagnostic tests in both point-of-care and
395 laboratory/diagnostic support settings.
- 396 ● Assessing the performance of new diagnostics (e.g., turnaround time, accuracy).
- 397 ● Auditing clinical services at multiple levels including individual clinicians, teams, units,
398 and organisations.
- 399 ● Assessing barriers to implementation and scalability of new interventions/drugs.
- 400 ● Incorporating structured qualitative experiential data from patients and communities.
- 401 ● Networking with different healthcare systems to borrow strength from each other
402 through shared programming algorithms and digital connections.

403

404 **4.3 Improving data actionability: the role of policymakers and healthcare leaders**

405 LASs will be built, run, and governed by collaborations of policymakers and leaders across
406 health and social care, public health, R&D and regulatory bodies (Figure 5). Their effective
407 and safe implementation will require careful consideration of patient/practitioner/public
408 engagement, data stewardship, implementation science, and regulation.



409
410
411
412
413
414
415
416

Figure 5: An AI model-informed precise approach to healthcare data flows in patient pathways. A schematic for the delivery and monitoring of precision antimicrobial treatment in the patient pathway by collaborations of policymakers and leaders in healthcare provision, public health, regulatory bodies, and R&D. This will be achieved by 'learning antimicrobial systems' built on connected dataflows. Improvements in patient and population care are driven by AI modelling of imprecision as a utility function, and fragmented dataflows (see Figure 3) have been replaced by integrated data-to-action loops.

417 **4.3.1 Actioning models of imprecision in real-time patient and population pathways**

418 Embedding real-time modelling of imprecision into decision support interfaces within LASS
419 would better inform clinicians of the impact of antimicrobial treatment. Ambient, wearable
420 and in-line biometric devices would provide real-time data inputs.^{65,66} Diagnostic and R&D
421 laboratories embedded in the LAS would target test implementation towards reducing
422 imprecision. Valuation of diagnostics based on their ability to reduce imprecision would
423 better target R&D and healthcare resources. Clinician- and patient-directed implementation
424 science would help determine how LAS-embedded decision aids could insert into the patient
425 pathway. In cases where the overall benefit of an intervention is debatable because
426 individual and societal impact exists in tension, this increased burden of knowledge will bring
427 with it difficult ethical decisions. These decisions cannot and must not be made by
428 algorithms. User interfaces built around 'moral' AI, however, could help clinicians and
429 policymakers navigate these complexities.⁶⁷

430 Integrating patient-level data with traditional, readily available aggregate data metrics (e.g.,
431 hospital-level AMR data) would help model and reduce antimicrobial treatment imprecision
432 on a larger scale. These models could complement or replace procedural markers such as
433 defined daily doses (DDDs). Unsupervised neural network models would form early warning
434 systems for AMS teams that sensitively detect imprecision. These areas would then be
435 explored through further data gathering and causation-based imprecision modelling. The
436 health consequences and resource impact of subsequent policies could then be simulated
437 based on modelling of imprecision.⁶⁸

438

439 **4.3.2 Actioning models of imprecision in research and development**

440 The impact of LASs would be continually assessed by teams of healthcare data scientists
441 using system-wide statistical analysis. Clinical trial endpoints could be adapted from models
442 of imprecision that enable ongoing questions about drugs and regimens to be addressed. A
443 traditional evidence base of interventional trials of LAS-embedded decision aids would be
444 continuously updated. An evaluation framework would facilitate participation in LAS-
445 embedded research at scale. Low-burden, adaptive platform trials would be embedded in
446 routine clinical care. State-of-the-art TREs with data engineering capacity would facilitate
447 storage of clean, secure, externally validated R&D data.

448 Valuation, research, development, regulation, and reimbursement based on imprecision
449 could incentivise the development of more targeted agents with useful characteristics (e.g.,
450 once daily administration). Health technology appraisals would leverage LAS data to develop
451 more equitable measures of allocating resource for new drugs and diagnostics. The impact
452 and value of delinked funding arrangements, contracts, and payment mechanisms within
453 and between health systems could be better assessed.

454

455 **4.3.3 Data stewardship and implementation science**

456 LASs would apply FAIR (find, access, interoperate, reuse) procedures. They would prioritise
457 data stewardship (including privacy, transparency, security, and governance), reproducibility
458 of evidence, and transferability of learning.⁶⁹ Embedding human-driven implementation
459 science (e.g., process evaluation, resource monitoring, qualitative methodology) and
460 governance in LASs will provide accountability that AI cannot fulfil.

461 Chronic system stress risks embedding organisational cultural psychologies of inertia and
462 impaired learning that may adapt poorly to the system changes required for LASs.^{70,71}
463 Experienced healthcare and public health organisational experts will therefore help facilitate
464 LAS adoption, implementation and maintenance.⁷² Clear lines of responsibility and
465 communication will ensure that learning from the system is fed back to stakeholders. These
466 measures will help sustain public trust, resource-efficiency, and feasibility of the system's
467 ongoing operation in a range of global settings.

468

469 **4.3.4 Patient and public involvement**

470 Given the social impact of AMR, co-production of LASs with practitioners, patients, and the
471 public is essential to ensure their operation is transparent, useful, and trustworthy. LAS data
472 must inform patients how they might maximally benefit from an antimicrobial treatment. This
473 will facilitate their role as decision makers in their own care. They must have access to their
474 own clinical information and understand how they can opt out of data collection. Involving the
475 public as stakeholders in LASs must drive a social conversation about the use of
476 antimicrobial agents as critical societal assets.

477

478 **4.3.5 Regulation and legislation of learning antimicrobial systems**

479 Regulatory agencies (e.g., Food and Drug Administration), lawmakers, and expert bodies
480 will need to develop positions on more flexible precision-based antimicrobial regimens.
481 Clarity about regulatory pathways will be required for AI-based decision support algorithms
482 (e.g., model-informed precision dosing). Legal positions must be clarified on data sharing
483 and data protection impact assessment that reflect the public health impact of AMR.

484 Preserving public trust in healthcare institutions and medical research will be a priority for
485 LASs. Legislating, vetting, monitoring, and regulating private companies' access to
486 healthcare data will be essential to ensure transparency and data security.
487 Code/algorithms/standard operating procedures must be open-source and not monetised,
488 enabling LASs across the globe to learn from one another.

489

490 **5. Conclusions**

491 Reducing antimicrobial treatment imprecision requires an adaptive, integrative, and
492 actionable representation of the evolving impacts of antimicrobial treatment on individuals
493 and society globally. Revolutions in availability of electronic healthcare data, computing, and
494 data science increasingly bring such intelligence within reach – clinically and scientifically
495 guided use of AI-based imprecision modelling could play a key role in improving our
496 understanding and uses of antimicrobial treatments. Better integrated dataflows will allow
497 these technologies to be embedded in LASs run by policymakers and leaders in healthcare,
498 public health, R&D, and regulatory bodies. The safe, practical, ethical, and sustainable
499 operation of LASs will be informed by state-of-the-art implementation science incorporating
500 clinician, patient, and public involvement. LASs built on models of imprecision could help
501 dampen 'boom and bust' cycles of antimicrobial development and AMR with globally
502 inclusive, ecologically, and organisationally sustainable models of infection management.

503

504

505 **6. References**

506

507 1 Nelson DW, Moore JE, Rao JR. Antimicrobial resistance (AMR): significance to food
508 quality and safety. *Food Qual Saf* 2019; **3**: 15–22.

509 2 Dadgostar P. Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist* 2019;
510 **Volume 12**: 3903–10.

511 3 Murray CJ, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance
512 in 2019: a systematic analysis. *The Lancet* 2022; **399**: 629–55.

513 4 Spellberg B, Nielsen TB, Gilbert DN, Shorr AF, Brass EP. Ensuring Sustainability of
514 Needed Antibiotics: Aiming for the DART Board. *Ann Intern Med* 2019; **171**: 580–2.

515 5 Basak S, Singh P, Rajurkar M. Multidrug Resistant and Extensively Drug Resistant
516 Bacteria: A Study. *J Pathog* 2016; **2016**: 4065603.

517 6 WHO publishes list of bacteria for which new antibiotics are urgently needed.
518 [https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)
519 [antibiotics-are-urgently-needed](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed) (accessed April 19, 2023).

520 7 Antimicrobial stewardship programmes in health-care facilities in low- and middle-income
521 countries: a WHO practical toolkit. *JAC-Antimicrob Resist* 2019; **1**: dlz072.

- 522 8 World Health Organization. Regional Office for Europe. Antimicrobial stewardship
523 interventions: a practical guide. World Health Organization. Regional Office for Europe,
524 2021 <https://apps.who.int/iris/handle/10665/340709> (accessed March 22, 2023).
- 525 9 Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. *Clin Microbiol*
526 *Infect* 2008; **14**: 15–21.
- 527 10Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and
528 initiatives to reduce the problem. *Ther Adv Drug Saf* 2014; **5**: 229–41.
- 529 11Struelens MJ. The epidemiology of antimicrobial resistance in hospital acquired infections:
530 problems and possible solutions. *BMJ* 1998; **317**: 652–4.
- 531 12Dutescu IA, Hillier SA. Encouraging the Development of New Antibiotics: Are Financial
532 Incentives the Right Way Forward? A Systematic Review and Case Study. *Infect Drug*
533 *Resist* 2021; **14**: 415–34.
- 534 13Velazquez-Meza ME, Galarde-López M, Carrillo-Quiróz B, Alpuche-Aranda CM.
535 Antimicrobial resistance: One Health approach. *Vet World* 2022; **15**: 743–9.
- 536 14Collins C, Dennehy D, Conboy K, Mikalef P. Artificial intelligence in information systems
537 research: A systematic literature review and research agenda. *Int J Inf Manag* 2021; **60**:
538 102383.
- 539 15Linardatos P, Papastefanopoulos V, Kotsiantis S. Explainable AI: A Review of Machine
540 Learning Interpretability Methods. *Entropy* 2020; **23**: 18.
- 541 16Nichols JA, Herbert Chan HW, Baker MAB. Machine learning: applications of artificial
542 intelligence to imaging and diagnosis. *Biophys Rev* 2018; **11**: 111–8.
- 543 17Jiang T, Gradus JL, Rosellini AJ. Supervised Machine Learning: A Brief Primer. *Behav*
544 *Ther* 2020; **51**: 675–87.
- 545 18Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum
546 antimicrobial use associated with no improvement in hospital antibiogram. *J Antimicrob*
547 *Chemother* 2004; **53**: 853–9.
- 548 19Veringa A, Ter Avest M, Span LFR, *et al.* Voriconazole metabolism is influenced by
549 severe inflammation: a prospective study. *J Antimicrob Chemother* 2017; **72**: 261–7.
- 550 20Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose
551 adjustment: facts and fables. *J Antimicrob Chemother* 2018; **73**: 564–8.
- 552 21Thorsted A, Nielsen EI, Friberg LE. Pharmacodynamics of immune response biomarkers
553 of interest for evaluation of treatment effects in bacterial infections. *Int J Antimicrob*
554 *Agents* 2020; **56**: 106059.
- 555 22Jamal J-A, Mueller BA, Choi GYS, Lipman J, Roberts JA. How can we ensure effective
556 antibiotic dosing in critically ill patients receiving different types of renal replacement
557 therapy? *Diagn Microbiol Infect Dis* 2015; **82**: 92–103.
- 558 23Chen IH, Nicolau DP. Augmented Renal Clearance and How to Augment Antibiotic
559 Dosing. *Antibiotics* 2020; **9**: 393.

- 560 24Saleh MAA, van de Garde EMW, van Hasselt JGC. Host-response biomarkers for the
561 diagnosis of bacterial respiratory tract infections. *Clin Chem Lab Med* 2019; **57**: 442–51.
- 562 25de Jong E, van Oers JA, Beishuizen A, *et al.* Efficacy and safety of procalcitonin guidance
563 in reducing the duration of antibiotic treatment in critically ill patients: a randomised,
564 controlled, open-label trial. *Lancet Infect Dis* 2016; **16**: 819–27.
- 565 26Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-
566 induced liver injury. *J Hum Genet* 2013; **58**: 317–26.
- 567 27Roberts JA, Udy AA, Jarrett P, *et al.* Plasma and target-site subcutaneous tissue
568 population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically
569 ill patients. *J Antimicrob Chemother* 2015; **70**: 1495–502.
- 570 28Akhtar M, Van Heukelom PG, Ahmed A, *et al.* Telemedicine Physical Examination
571 Utilizing a Consumer Device Demonstrates Poor Concordance with In-Person Physical
572 Examination in Emergency Department Patients with Sore Throat: A Prospective Blinded
573 Study. *Telemed J E-Health Off J Am Telemed Assoc* 2018; **24**: 790–6.
- 574 29Wei W-Q, Leibson CL, Ransom JE, *et al.* Impact of data fragmentation across healthcare
575 centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying
576 subjects with type 2 diabetes mellitus. *J Am Med Inform Assoc JAMIA* 2012; **19**: 219–24.
- 577 30Staa T-P van, Goldacre B, Buchan I, Smeeth L. Big health data: the need to earn public
578 trust. *BMJ* 2016; **354**: i3636.
- 579 31Herd P, Moynihan D. Health care administrative burdens: Centering patient experiences.
580 *Health Serv Res* 2021; **56**: 751–4.
- 581 32Davari M, Khorasani E, Tigabu BM. Factors Influencing Prescribing Decisions of
582 Physicians: A Review. *Ethiop J Health Sci* 2018; **28**: 795–804.
- 583 33Liu C, Wang D, Duan L, Zhang X, Liu C. Coping With Diagnostic Uncertainty in Antibiotic
584 Prescribing: A Latent Class Study of Primary Care Physicians in Hubei China. *Front*
585 *Public Health* 2021; **9**: 741345.
- 586 34Warreman EB, Lambregts MMC, Wouters RHP, *et al.* Determinants of in-hospital
587 antibiotic prescription behaviour: a systematic review and formation of a comprehensive
588 framework. *Clin Microbiol Infect* 2019; **25**: 538–45.
- 589 35Poss-Doering R, Kamradt M, Stuermlinger A, *et al.* The complex phenomenon of
590 dysrational antibiotics prescribing decisions in German primary healthcare: a qualitative
591 interview study using dual process theory. *Antimicrob Resist Infect Control* 2020; **9**: 6.
- 592 36Sarikonda KV, Micek ST, Doherty JA, Reichley RM, Warren D, Kollef MH. Methicillin-
593 resistant *Staphylococcus aureus* nasal colonization is a poor predictor of intensive care
594 unit-acquired methicillin-resistant *Staphylococcus aureus* infections requiring antibiotic
595 treatment. *Crit Care Med* 2010; **38**: 1991.
- 596 37Prescott HC, Iwashyna TJ. Improving Sepsis Treatment by Embracing Diagnostic
597 Uncertainty. *Ann Am Thorac Soc* 2019; **16**: 426–9.
- 598 38Ilg A, Moskowitz A, Konanki V, *et al.* Performance of the CURB-65 Score in Predicting
599 Critical Care Interventions in Patients Admitted with Community Acquired Pneumonia.
600 *Ann Emerg Med* 2019; **74**: 60–8.

- 601 39Li H-K, Rombach I, Zambellas R, *et al.* Oral versus Intravenous Antibiotics for Bone and
602 Joint Infection. *N Engl J Med* 2019; **380**: 425–36.
- 603 40McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical
604 implementation of pharmacogenomics. *Ther Clin Risk Manag* 2007; **3**: 751–9.
- 605 41Sjövall F, Lanckohr C, Bracht H. What’s new in therapeutic drug monitoring of
606 antimicrobials? *Intensive Care Med* 2023; published online May 3. DOI:10.1007/s00134-
607 023-07060-5.
- 608 42Geli P, Laxminarayan R, Dunne M, Smith DL. “One-Size-Fits-All”? Optimizing Treatment
609 Duration for Bacterial Infections. *PLoS ONE* 2012; **7**: e29838.
- 610 43Barr D, Seaton R. Outpatient parenteral -antimicrobial therapy (OPAT) and the general
611 -physician. *Clin Med* 2013; **13**: 495–9.
- 612 44Charani E, Ahmad R, Rawson TM, Castro-Sanchèz E, Tarrant C, Holmes AH. The
613 Differences in Antibiotic Decision-making Between Acute Surgical and Acute Medical
614 Teams: An Ethnographic Study of Culture and Team Dynamics. *Clin Infect Dis* 2019; **69**:
615 12–20.
- 616 45Banu S, Rahman SMM, Khan MSR, *et al.* Discordance across Several Methods for Drug
617 Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Single
618 Laboratory. *J Clin Microbiol* 2014; **52**: 156–63.
- 619 46Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of
620 community-acquired bacteremic acute pyelonephritis. *J Infect* 2011; **62**: 159–64.
- 621 47Nathwani D, Lawson W, Dryden M, *et al.* Implementing criteria-based early switch/early
622 discharge programmes: a European perspective. *Clin Microbiol Infect* 2015; **21**: S47–55.
- 623 48Cyriac JM, James E. Switch over from intravenous to oral therapy: A concise overview. *J*
624 *Pharmacol Pharmacother* 2014; **5**: 83–7.
- 625 49O’Kelly B, Cronin C, Connellan D, *et al.* Antibiotic prescribing patterns in patients
626 hospitalized with COVID-19: lessons from the first wave. *JAC-Antimicrob Resist* 2021; **3**:
627 dlab085.
- 628 50Cremers S, Guha N, Shine B. Therapeutic drug monitoring in the era of precision
629 medicine: opportunities! *Br J Clin Pharmacol* 2016; **82**: 900–2.
- 630 51Dean L, Kane M. Gentamicin Therapy and MT-RNR1 Genotype. In: Pratt VM, Scott SA,
631 Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries.
632 Bethesda (MD): National Center for Biotechnology Information (US), 2012.
633 <http://www.ncbi.nlm.nih.gov/books/NBK285956/> (accessed March 24, 2023).
- 634 52Abdul-Aziz MH, Brady K, Cotta MO, Roberts JA. Therapeutic Drug Monitoring of
635 Antibiotics: Defining the Therapeutic Range. *Ther Drug Monit* 2022; **44**: 19–31.
- 636 53Adembri C, Novelli A, Nobili S. Some Suggestions from PK/PD Principles to Contain
637 Resistance in the Clinical Setting—Focus on ICU Patients and Gram-Negative Strains.
638 *Antibiotics* 2020; **9**: 676.
- 639 54Llewelyn MJ, Fitzpatrick JM, Darwin E, *et al.* The antibiotic course has had its day. *BMJ*
640 2017; **358**: j3418.

- 641 55Llewelyn MJ, Budgell EP, Laskawiec-Szkonter M, *et al.* Antibiotic review kit for hospitals
642 (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial. *Lancet Infect Dis*
643 2023; **23**: 207–21.
- 644 56Cobo J, Escudero-Sanchez R. Suppressive Antibiotic Treatment in Prosthetic Joint
645 Infections: A Perspective. *Antibiotics* 2021; **10**: 743.
- 646 57Doub JB. Treatment of Recurrent Severe Cellulitis with a Pill in Pocket Approach. *Infect*
647 *Chemother* 2022; **54**: 382–7.
- 648 58Langford BJ, Brown KA, Diong C, *et al.* The Benefits and Harms of Antibiotic Prophylaxis
649 for Urinary Tract Infection in Older Adults. *Clin Infect Dis* 2021; **73**: e782–91.
- 650 59Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management,
651 analysis and future prospects. *J Big Data* 2019; **6**: 54.
- 652 60Gifu D. AI-backed OCR in Healthcare. *Procedia Comput Sci* 2022; **207**: 1134–43.
- 653 61Real-time continuous measurement of lactate through a minimally invasive microneedle
654 patch: a phase I clinical study | BMJ Innovations.
655 <https://innovations.bmj.com/content/8/2/87> (accessed March 24, 2023).
- 656 62Banerjee R, Patel R. Molecular diagnostics for genotypic detection of antibiotic resistance:
657 current landscape and future directions. *JAC-Antimicrob Resist* 2023; **5**: dlad018.
- 658 63Green MA, García-Fiñana M, Barr B, *et al.* Evaluating social and spatial inequalities of
659 large scale rapid lateral flow SARS-CoV-2 antigen testing in COVID-19 management: An
660 observational study of Liverpool, UK (November 2020 to January 2021). *Lancet Reg*
661 *Health - Eur* 2021; **6**: 100107.
- 662 64Eppich W, Reedy G. Advancing healthcare simulation research: innovations in theory,
663 methodology, and method. *Adv Simul* 2022; **7**: 23.
- 664 65Iqbal SMA, Mahgoub I, Du E, Leavitt MA, Asghar W. Advances in healthcare wearable
665 devices. *Npj Flex Electron* 2021; **5**: 1–14.
- 666 66Haque A, Milstein A, Fei-Fei L. Illuminating the dark spaces of healthcare with ambient
667 intelligence. *Nature* 2020; **585**: 193–202.
- 668 67Bolton WJ, Badea C, Georgiou P, Holmes A, Rawson TM. Developing moral AI to support
669 decision-making about antimicrobial use. *Nat Mach Intell* 2022; **4**: 912–5.
- 670 68Merlin T, Lehman S, Hiller JE, Ryan P. The ‘linked evidence approach’ to assess medical
671 tests: a critical analysis. *Int J Technol Assess Health Care* 2013; **29**: 343–50.
- 672 69Wilkinson MD, Dumontier M, Aalbersberg IJ, *et al.* The FAIR Guiding Principles for
673 scientific data management and stewardship. *Sci Data* 2016; **3**: 160018.
- 674 70Mareš J. Resistance of health personnel to changes in healthcare. *Kontakt* 2018; **20**:
675 e262–72.
- 676 71Rushmer R, Davies HTO. Unlearning in health care. *BMJ Qual Saf* 2004; **13**: ii10–5.
- 677 72Bauer MS, Damschroder L, Hagedorn H, Smith J, Kilbourne AM. An introduction to
678 implementation science for the non-specialist. *BMC Psychol* 2015; **3**: 32.

679 **Contributors**

680

681 AH – writing, editing, diagrams; NR – diagrams; SA – comments, editing; BW – comments,
682 editing; AG – comments, editing; IB – comments, editing; WH – comments, editing; AGM –
683 writing, comments, editing.

684

685 **Declaration of Interests**

686 AH declares consulting work for Pfizer outside the submitted work, NR/AG/SA have no
687 interests to declare, BW sits on the board of the York Health Economics Consortium, IB holds
688 a senior investigator award with NIHR, personal fees and other from AstraZeneca outside the
689 submitted work, WH holds or has held research grants with UKRI, EU, F2G, Spero
690 Therapeutics, Antabio, Pfizer, Bugworks, Phico Therapeutics, BioVersys, Global Antibiotic
691 Research & Development Partnership (GARDP), and NAEJA-RGM. WH is or has been a
692 consultant for Appili Therapeutics, F2G, Spero Therapeutics, NAEJA-RGM, Centauri, Pfizer,
693 Phico Therapeutics, Pulmocide, Amplyx, Mundipharma Research, and VenatoRx. WH is a
694 member of the Specialist Advisory Committee for GARDP and the Specialty National co-lead
695 for Infectious Diseases for the National Institute of Health Research.

696

697 **Role of the Funding Source**

698 There were no sources of funding for this paper.